93 completed, 29 terminated, 10 active not recruiting, 8 withdrawn. 83 Phase 1, 63 Phase 2, 13 Not applicable, 2 Early Phase 1, 1 Phase 3.
Follow Recurrent Marginal Zone Lymphoma: new trials by email Literature Review of Recurrent Marginal Zone Lymphoma trials Research Report on Recurrent Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Venetoclax, Lenalidomide, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | Thomas Jefferson University | 4 | 2020-10-16 | 2026-10-02 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma Carfilzomib, Laboratory Biomarker Analysis, Rituximab - Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 2 | Terminated | University of Washington | 4 | 2017-12-18 | 2020-01-18 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 11 | 2017-08-15 | 2026-05-04 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Barbara Ann Karmanos Cancer Institute | 43 | 2017-06-20 | 2026-10-23 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma | Phase 1 | Active not recruiting | Beth Christian | 22 | 2017-02-21 | 2026-09-24 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
Showing 20 of 141. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (141) · Lymphoma, Follicular (139) · Lymphoma, Mantle-Cell (122) · Leukemia, Lymphocytic, Chronic, B-Cell (119) · Lymphoma, Large B-Cell, Diffuse (111) · Lymphoma, Non-Hodgkin (107) · Waldenstrom Macroglobulinemia (100) · Burkitt Lymphoma (95) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (93) · Lymphoma, Large-Cell, Immunoblastic (86) · Hodgkin Disease (69) · Lymphoma, T-Cell, Cutaneous (68) · Mycosis Fungoides (67) · Sezary Syndrome (67) · Lymphoma, Large-Cell, Anaplastic (60)
Hemic and Lymphatic Diseases (141) · Immune System Diseases (141) · Immunoproliferative Disorders (141) · Lymphatic Diseases (141) · Lymphoproliferative Disorders (141) · Neoplasms by Histologic Type (141) · Lymphoma (140) · Neoplasms (140) · Hematologic Diseases (134) · Lymphoma, B-Cell (127) · Leukemia (122) · Leukemia, Lymphoid (121) · Chronic Disease (119) · Disease Attributes (119) · Leukemia, B-Cell (119)
Rituximab (30) · fludarabine phosphate (25) · Peripheral Blood Stem Cell Transplantation (23) · Whole-Body Irradiation (20) · Mycophenolic Acid (19) · Cyclophosphamide (18) · Cyclosporine (14) · Lenalidomide (14) · Tacrolimus (10) · Bortezomib (9) · Etoposide (9) · Flow Cytometry (9) · Bendamustine Hydrochloride (7) · Busulfan (7) · Filgrastim (7)
National Cancer Institute (NCI) (54) · Fred Hutchinson Cancer Center (29) · City of Hope Medical Center (8) · Case Comprehensive Cancer Center (6) · Mayo Clinic (6) · Roswell Park Cancer Institute (5) · University of Washington (4) · Barbara Ann Karmanos Cancer Institute (2) · Kami Maddocks, MD (2) · Ohio State University Comprehensive Cancer Center (2) · Robert Lowsky (2) · Wake Forest University Health Sciences (2) · Academic and Community Cancer Research United (1) · Amir Mortazavi (1) · Beth Christian (1)
United States (135) · Italy (7) · Germany (5) · Canada (4) · Denmark (1)
Ajay Gopal (7) · David Maloney (6) · Brenda Sandmaier (5) · Kami Maddocks, MD (4) · Paul Martin (3) · Anas Younes (2) · Brenda Cooper (2) · George Chen (2) · John Byrd (2) · Joseph M Tuscano (2) · Leslie Popplewell (2) · Patricia LoRusso (2) · Philip McCarthy (2) · Ramesh Ramanathan (2) · Ryotaro Nakamura (2)
PMID 32499241, PMID 34515338, PMID 19900571, PMID 20837940, PMID 21300924, PMID 21508413, PMID 22259028, PMID 22308288, PMID 23256542, PMID 24241210, PMID 24474568, PMID 24530971, PMID 25085357, PMID 25355819, PMID 26213141, PMID 26764356, PMID 26943915, PMID 27118452, PMID 28270022, PMID 28314788, PMID 28424162, PMID 28817727, PMID 29292843, PMID 29572391, PMID 30454872, PMID 31388792, PMID 31481800, PMID 31617432, PMID 32628342, PMID 33420905, PMID 33492438, PMID 33785483, PMID 34320785, PMID 34492703, PMID 34780125, PMID 36282798, PMID 36631449, PMID 39161543
P30CA015704 (16), U01CA076576 (9), P30CA015083 (6), U01CA062505 (6), P01CA018029 (5), P30CA016058 (5), U01CA062487 (5), U01CA062491 (5), U01CA062502 (5), U01CA099168 (5), P30CA033572 (4), N01CM17003 (3), N01CM62202 (3), P01CA044991 (3), P01CA078902 (3)